ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "ASH 2025 LBA BRUIN-CLL 313 Update: Pirtobrutinib vs Bendamustine/Rituximab in 1L CLL"
Episode Synopsis
This week’s episode will be focusing on an update of a late-breaking abstract presented at ASH 2025 this past week: the Phase 3 BRUIN-CLL 313 trial looking at Pirtobrutinib vs Bendamustine/Rituximab in 1L Chronic Lymphocytic Leukemia (CLL).
More episodes of the podcast Two Onc Docs
Hodgkin Lymphoma 2025 UPDATE
24/11/2025
Anal Cancer 2025 UPDATE
17/11/2025
Urothelial ESMO 2025 Updates
10/11/2025
Board Review Tidbits
03/11/2025
Porphyria
27/10/2025
Metastatic Breast Cancer 2025 UPDATE
20/10/2025
Localized Breast Cancer 2025 UPDATE
13/10/2025
In God we trust